Rheumatoid arthritis patient advocates for continued access to medication in North Dakota

The bond between patients and healthcare providers has always been based on trust and transparency

The FDA’s approval of Zarxio, the first biosimilar product authorized for use in the United States, led to a flurry of predictions Friday about billions of dollars in savings and expanded access to treatment for patients. But what exactly are biosimilars, and why are they being hailed in this way?

Very recently during the 64th Legislature in the State of Washington, House Bill 1675 was introduced relating to the prescription of biological products and interchangeable biological products.

A recent decision by Facebook to limit the content we see in our newsfeeds could have far-­reaching
and potentially deleterious unintended consequences for the global nonprofit and advocacy
communities.

The U.S. Food and Drug Administration (FDA) approved the first biosimilar in early March. Three others are undergoing the agency’s review, which is just the tip of the iceberg…

Steve Marmaras on AM Baton Rouge discussing about biosimilar legislation.

We can all likely agree we’re lucky drugs aren’t recalled as frequently as cars.

Would you want your pharmacist to tell you and your doctor if they substituted your biologic medication with a similar, but not identical drug? Of course you would. But as biosimilars — a less expensive mimic of Biologics — are introduced on the U.S. market, individual states are deciding how and when they can be […]

Watch the Video